- Home
- APLS vs RARE Comparison
APLS vs RARE Comparison
Compare APLS & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLS | RARE |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.2B |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | APLS | RARE |
|---|---|---|
| Price | $23.62 | $36.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 15 |
| Target Price | $33.11 | ★ $85.20 |
| AVG Volume (30 Days) | ★ 2.4M | 1.3M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,016,397,000.00 | $630,598,000.00 |
| Revenue This Year | $29.00 | $19.09 |
| Revenue Next Year | N/A | $20.62 |
| P/E Ratio | $65.98 | ★ N/A |
| Revenue Growth | ★ 42.11 | 20.63 |
| 52 Week Low | $16.10 | $25.81 |
| 52 Week High | $35.72 | $50.00 |
Technical Indicators
Market Signals| Indicator | APLS | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 62.06 | 62.08 |
| Support Level | $20.51 | $33.16 |
| Resistance Level | $21.72 | $34.77 |
| Average True Range (ATR) | 0.81 | 1.52 |
| MACD | 0.51 | 0.36 |
| Stochastic Oscillator | 92.66 | 83.52 |
Price Performance
Historical ComparisonAbout APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.